The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis
Abstract
Entecavir is a potent antiviral agent with high genetic barrier to resistance, hence it is currently recommended as first-line antiviral therapy for chronic hepatitis B (CHB). The aim of this study was to investigate the efficacy of entecavir on clinical outcomes and deaths. It was a retrospective-prospective cohort study based on two cohorts of patients. The entecavir cohort included consecutive CHB patients who had received entecavir 0.5 mg/day for at least 12 months. The historical control cohort included untreated patients recruited since 1997 who underwent routine clinical care. The primary outcome was the 5-year cumulative probability of hepatic events, defined as any cirrhotic complications, hepatocellular carcinoma (HCC), and/or liver-related mortality. A total of 1,446 entecavir-treated patients (72% men; age, 51 ± 12 years; follow-up, 36 ± 13 months) and 424 treatment-naïve patients (65% men; age, 41 ± 13 years; follow-up, 114 ± 31 months) were studied. Overall, there was no difference in hepatic events between the entecavir and control cohorts. Among patients with liver cirrhosis (482 entecavir-treated, 69 treatment-naïve), entecavir-treated patients had reduced risks of all clinical outcomes when compared with treatment-naïve patients with cirrhosis after adjusted for model for end-stage liver disease score: hepatic events (hazard ratio [HR], 0.51; 95% confidence interval [CI], 0.34-0.78; P = 0.002), HCC (HR, 0.55; 95% CI, 0.31-0.99; P = 0.049), liver-related mortality (HR, 0.26; 95% CI, 0.13-0.55; P < 0.001), and all-cause mortality (HR, 0.34; 95% CI, 0.18-0.62; P < 0.001). Entecavir-treated patients with cirrhosis who failed to achieve undetectable hepatitis B virus DNA (105/482 [22%]) had comparable risk of hepatic events as the untreated patients. Conclusion: Entecavir therapy reduces the risks of hepatic events, HCC, liver-related and all-cause mortality of CHB patients with liver cirrhosis in 5 years, particularly among those who had maintained viral suppression. (Hepatology 2013;58:1537–1547)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
A Model to Predict Survival in Patients With End–Stage Liver Disease
Kamath, P. S., Wiesner, R. H., Malinchoc, M., Kremers, W., Therneau, T. M., Kosberg, C. L., D'Amico, G., Dickson, R. E., & Kim, R. W. (2001) · Hepatology · doi:10.1053/jhep.2001.22172 · Cited by 4,975
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.010 · Cited by 2,925
Chronic hepatitis B: Update 2009 #
Lok, A. S. F., & McMahon, B. J. (2009) · Hepatology · doi:10.1002/hep.23190 · Cited by 2,831
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033364 · Cited by 2,266
Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load
Iloeje, U. H., Yang, H., Su, J., Jen, C., You, S., & Chen, C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.016 · Cited by 1,528
A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B
Chang, T.-T., Gish, R. G., de Man, R., Gadano, A., Sollano, J., Chao, Y.-C., Lok, A. S., Han, K.-H., Goodman, Z., Zhu, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051285 · Cited by 1,444
Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B
Lai, C.-L., Shouval, D., Lok, A. S., Chang, T.-T., Cheinquer, H., Goodman, Z., DeHertogh, D., Wilber, R., Zink, R. C., Cross, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051287 · Cited by 1,188
Peck, M., Craxì, A., Fried, M., & Zeuzem, S. (2013) · Cited by 1,079
Chang, T.-T., Liaw, Y.-F., Wu, S.-S., Schiff, E., Han, K.-H., Lai, C.-L., Safadi, R., Lee, S. S., Halota, W., Goodman, Z., et al. (2010) · Hepatology · doi:10.1002/hep.23785 · Cited by 972
Self-citationAsian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update
Liaw, Y.-F., Leung, N., Kao, J.-H., Piratvisuth, T., Gane, E., Han, K.-H., Guan, R., Lau, G. K. K., Locarnini, S., & for the Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver (2008) · Hepatology International · doi:10.1007/s12072-008-9080-3 · Cited by 867
Tsochatzis, E. A., Gurusamy, K. S., Ntaoula, S., Cholongitas, E., Davidson, B. R., & Burroughs, A. K. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.07.033 · Cited by 709
Chang, T.-T., Lai, C.-L., Yoon, S. K., Lee, S. S., Coelho, H. S. M., Carrilho, F. J., Poordad, F., Halota, W., Horsmans, Y., Tsai, N., et al. (2010) · Hepatology · doi:10.1002/hep.23327 · Cited by 588
Self-citationClinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers
Wong, V. W.-S., Chan, S. L., Mo, F., Chan, T.-C., Loong, H. H.-F., Wong, G. L.-H., Lui, Y. Y.-N., Chan, A. T.-C., Sung, J. J.-Y., Yeo, W., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2675 · Cited by 502
Self-citationYuen, M., Wong, D. K., Fung, J., Ip, P., But, D., Hung, I., Lau, K., Yuen, J. C., & Lai, C. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.008 · Cited by 409
Meta‐analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma
SUNG, J. J. Y., TSOI, K. K. F., WONG, V. W. S., LI, K. C. T., & CHAN, H. L. Y. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03816.x · Cited by 370
Self-citationChan, H. L.-Y., Tse, C.-H., Mo, F., Koh, J., Wong, V. W.-S., Wong, G. L.-H., Lam Chan, S., Yeo, W., Sung, J. J.-Y., & Mok, T. S.-K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.2043 · Cited by 301
Self-citationLiaw, Y., Raptopoulou‐Gigi, M., Cheinquer, H., Sarin, S. K., Tanwandee, T., Leung, N. W. Y., Peng, C., Myers, R. P., Brown, R. S., Jeffers, L. J., et al. (2011) · Hepatology · doi:10.1002/hep.24361 · Cited by 232
Wong, V. W., Yu, J., Cheng, A. S., Wong, G. L., Chan, H., Chu, E. S., Ng, E. K., Chan, F. K., Sung, J. J., & Chan, H. L. (2009) · International Journal of Cancer · doi:10.1002/ijc.24281 · Cited by 208
Self-citationZoutendijk, R., Reijnders, J. G., Zoulim, F., Brown, A., Mutimer, D. J., Deterding, K., Hofmann, W. P., Petersen, J., Fasano, M., Buti, M., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302024 · Cited by 183
Leung, N., Peng, C., Hann, H., Sollano, J., Lao‐Tan, J., Hsu, C., Lesmana, L., Yuen, M., Jeffers, L., Sherman, M., et al. (2009) · Hepatology · doi:10.1002/hep.22658 · Cited by 182
Wong, G. L., Wong, V. W., Tan, G., Ip, K., Lai, W., Li, Y., Mak, M. S., Lai, P. B. S., Sung, J. J. �., & Chan, H. L. (2007) · Liver International · doi:10.1111/j.1478-3231.2007.01576.x · Cited by 123
Self-citationChan, H. L., Chui, A. K. K., Lau, W., Chan, F. K. L., Wong, M., Tse, C., Rao, A. R., Wong, J., & Sung, J. J. �. (2002) · Journal of Medical Virology · doi:10.1002/jmv.10185 · Cited by 83
Self-citationMeta‐analysis: reduction in hepatic events following interferon‐alfa therapy of chronic hepatitis B
Wong, G. L., Yiu, K. K. L., Wong, V. W., Tsoi, K. K. F., & Chan, H. L. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04447.x · Cited by 56
Self-citationWong, G. L., Wong, V. W., Chan, H., Tse, P. C., Wong, J., Chim, A. M.-L., Yiu, K. K. L., Chu, S. H. ‐., & Chan, H. L. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05098.x · Cited by 56
Self-citationSurrogate End Points and Long-Term Outcome in Patients With Chronic Hepatitis B
Wong, V. W., Wong, G. L., Chim, A. M., Choi, P. C., Chan, A. W. H., Tsang, S. W., Hui, A., Chan, H., Sung, J. J., & Chan, H. L. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.05.025 · Cited by 51
Self-citation
Cited by
Burden of liver diseases in the world
Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.014 · Cited by 3,783
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
Self-citationGlobal burden of liver disease: 2023 update
Devarbhavi, H., Asrani, S. K., Arab, J. P., Nartey, Y. A., Pose, E., & Kamath, P. S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.017 · Cited by 2,267
Omata, M., Cheng, A.-L., Kokudo, N., Kudo, M., Lee, J. M., Jia, J., Tateishi, R., Han, K.-H., Chawla, Y. K., Shiina, S., et al. (2017) · Hepatology International · doi:10.1007/s12072-017-9799-9 · Cited by 2,171
Metadata
- Authors
- Wong, G. L.-H., Chan, H. L.-Y., Mak, C. W.-H., Lee, S. K.-Y., Ip, Z. M.-Y., Lam, A. T.-H., Iu, H. W.-H., Leung, J. M.-S., Lai, J. W.-Y., Lo, A. O.-S., Chan, H.-Y., & Wong, V. W.-S.
- Venue
- Hepatology
- Published
- 2013-11
- Volume
- 58
- Issue
- 5
- Pages
- 1537-1547
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1972926465
- Cited by
- 488
- References
- 26
- FWCI
- 35.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.